WASHINGTON, D.C. – The Global CEO Initiative on Alzheimer’s Disease (CEOi) today announced that Drew Holzapfel, will join the CEOi as Executive Director. With his addition to the CEOi, Mr. Holzapfel brings a wealth of experience from positions in global and U.S. biotechnology, pharmaceutical and government organizations to the fight against Alzheimer’s disease.
No front page content has been created yet.
Latest from the Newsroom
April 1, 2013
March 13, 2013
Pharma CEOs team up to tackle Alzheimer’s-
Call for Global Alzheimer’s Action Plan to prevent and treat neurological condition by 2025
March 5, 2013
Brussels – Today, March 5, during a joint conference of the Irish Council Presidency and the European Parliament, leading global corporations urged the development of a Global Alzheimer’s Action Plan to diagnose, prevent and treat Alzheimer's disease by 2025.
The Global CEO Initiative on Alzheimer’s Disease (CEOi), a newly-formed private-sector initiative designed to collaborate with the public sector, non-profit community and academia, is a response to the call of political leaders for industry to help address this unprecedented global health, societal and fiscal threat. Today’s event is the first public event in a series of activities and actions across the globe for the CEOi.
Why Alzheimer's?
36 million people worldwide are currently living with Alzheimer's and dementia.
115 million people will be living with Alzheimer's and dementia by 2050 if aggressive action isn't taken now.
Main menu
